Chengdu Zenitar Biomedical Technology Co., Ltd
Clinical trials sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- A single-center, non-randomized, open-label, single-dose mass balance study of [¹⁴C]Purinostat mesylate for injection in healthy participants Results expected Oct 2026 (estimated)
- New hope for Hard-to-Treat lymphoma: experimental drug shows promise Results expected Dec 2026 (estimated)
- Can common drugs change how a new cancer medicine works? Results expected Dec 2026 (estimated)
- Can a new experimental pill be safely given to people? Results expected Jul 2027 (estimated)
- New pill could help control blood disorder when standard drugs fail Results expected Jul 2027 (estimated)